CN101912446A - Application of forsythia chloroform extracts to preparing medicine for treating diabetes mellitus - Google Patents

Application of forsythia chloroform extracts to preparing medicine for treating diabetes mellitus Download PDF

Info

Publication number
CN101912446A
CN101912446A CN 201010256475 CN201010256475A CN101912446A CN 101912446 A CN101912446 A CN 101912446A CN 201010256475 CN201010256475 CN 201010256475 CN 201010256475 A CN201010256475 A CN 201010256475A CN 101912446 A CN101912446 A CN 101912446A
Authority
CN
China
Prior art keywords
forsythia
shp2
fructus forsythiae
extract
chloroform
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 201010256475
Other languages
Chinese (zh)
Other versions
CN101912446B (en
Inventor
吕忠显
陈海峰
石涛
布艳艳
陈全成
蒙明慧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xiamen University
Original Assignee
Xiamen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xiamen University filed Critical Xiamen University
Priority to CN2010102564759A priority Critical patent/CN101912446B/en
Publication of CN101912446A publication Critical patent/CN101912446A/en
Application granted granted Critical
Publication of CN101912446B publication Critical patent/CN101912446B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides the application of forsythia chloroform extracts to preparing a medicine for treating diabetes mellitus, which relates to Chinese herb extracts. The invention provides the application of the forsythia chloroform extracts to preparing a tyrosine phosphatase SHP2 accelerant and a medicine for preparing diabetes mellitus. The preparation method of the forsythia chloroform extracts comprises the following steps of: soaking dry forsythia with ethanol; combining extracting solutions after being heated and refluxed; decompressing and drying to obtain a total forsythia extract; mixing the total forsythia extract with diatomite or suspending the total forsythia extract with water; extracting by adopting chloroform; decompressing and concentrating; and drying to obtain the forsythia chloroform extracts. The forsythia chloroform extracts can promote the activity of the tyrosine phosphatase SHP2, plays a role of reducing blood sugar concentration and can be widely used for preparing the tyrosine phosphatase SHP2 accelerant and the medicine for preparing diabetes mellitus.

Description

The application of chloroform extract of Fructus Forsythiae in preparation treatment diabetes medicament
Technical field
The present invention relates to a kind of Chinese medicine extract, the particularly application of chloroform extract of Fructus Forsythiae in preparation treatment diabetes medicament.
Background technology
Tyrosine phosphatase SHP2 is an important member in tyrosine phosphatase (tyrosine phosphatase) family, what its discovery made that people recognize for the first time that protein kinase contends with agent and the mechanism of contending with exists (Feng GS, Hui CC, Pawson T:SH2-containing phosphotyrosine phosphatase as a target of protein-tyrosine kinases.Science 1993,259 (5101): 1607-1611).A large amount of subsequently systematic studys show, SHP2 not merely suppresses the signal conduction as the contending with agent of protein kinase signal, also can promote various kinds of cell matter signal (2.Feng GS:Shp2-mediated molecular signaling in control of embryonic stem cell self-renewal and differentiation.Cell Res 2007,17 (1): 37-41.3.Feng GS:Shp2 as a therapeutic target for leptin resistance and obesity.Expert Opin Ther Targets 2006,10 (1): 135-142.4.Mohi MG, Neel BG:The role of Shp2 (PTPN11) in cancer.Curr Opin Genet Dev 2007,17 (1): 23-30.).Aspect metabolic disease, by a series of tissue specificity transgenic animal models, the normal activity of proof SHP2 is the key signal that prevents diabetes, its active reduction is then brought out diabetes (5.Zhang SS, Hao E, Yu J, et al.Coordinated regulation by Shp2 tyrosine phosphatase of signaling events controlling insulin biosynthesis in pancreatic beta-cells.Proc Natl Acad Sci U S A 2009,106 (18): 7531-7536; 6.Princen F, Bard E, Sheikh F, et al.Deletion of Shp2 tyrosine phosphatase in muscle leads to dilated cardiomyopathy, insulin resistance, and premature death.Mol Cell Biol 2009,29 (2): 378-388; 7.Krajewska M, Banares S, Zhang EE, et al.Development of diabesity in mice with neuronal deletion of Shp2 tyrosine phosphatase.Am J Pathol 2008,172 (5): 1312-1324; 8.Zhang EE, Chapeau E, Hagihara K, et al.Neuronal Shp2 tyrosine phosphatase controls energy balance and metabolism.Proc Natl Acad Sci U S A 2004,101 (45): 16064-16069; 9.Bard-Chapeau EA, Yuan J, Droin N, et al.Concerted functions of Gab 1and Shp2 in liver regeneration and hepatoprotection.Mol Cell Biol 2006,26 (12): 4664-4674; 10.Bard-Chapeau EA, Hevener AL, Long S, et al.Deletion of Gab 1in the liver leads to enhanced glucose tolerance and improved hepatic insulin action.Nat Med 2005,11 (5): 567-571.).SHP2 is the crucial modulin of diabetes and obesity, SHP2 is after forebrain is rejected, obesity takes place in mice, body weight is apparently higher than normal mouse, blood insulin and leptin raise, produce type ii diabetes symptoms such as hyperglycemia, insulin, leptin opposing, the typical complication of multiple diabetes then appears in development subsequently.And SHP2 is when forebrain continuous expression high activity, no matter the mice feed how much, is not got fat.In addition, use SHP2 and reject or activated transgenic mice, prove that SHP2 has promotion and safeguards secretion of insulin, promotes the glycometabolic effect of insulin regulation and control hepatocyte at liver, pancreatic tissue specificity.
Fructus Forsythiae is the dry fruit of Oleaceae plant Fructus Forsythiae Forsythia suspensa (Thunb.) Vahl.Cold nature, bitter in the mouth.Has heat-clearing and toxic substances removing, the effect of dispersing swelling and dissipating binds.Tradition is used and is mainly used in treatment of diseases such as affection due to external wind and heat, laryngopharynx swelling and pain, carbuncle furuncle, scrofula.Chemical constituent in the Fructus Forsythiae mainly is lignanoids, flavonoid, phenethanol and glycoside thereof and the natural alcohols of C6~C2, terpenoid etc.Pharmacological research shows, that Fructus Forsythiae has is antibiotic, antiviral, antiinflammatory, treatment cardiovascular disease, antiendotoxin, inhibition elastin laminin enzyme activity, suppress pharmacological actions such as cAMP di-phosphate ester enzyme activity, hepatoprotective effect (11. Zhang Haiyans. the progress of Fructus Forsythiae chemical constituent and pharmacologically active. Chinese crude drug, 2000,23 (10): 10).But report is not studied in the application of Fructus Forsythiae aspect blood sugar lowering, therefore, is target spot with SHP2, and the Fructus Forsythiae hypoglycemic medicine of development of new has very significant meaning.
Summary of the invention
The object of the present invention is to provide the application of chloroform extract of Fructus Forsythiae in preparation tyrosine phosphatase SHP2 promoter and preparation treatment diabetes medicament.
Described chloroform extract of Fructus Forsythiae prepares by the following method: through soak with ethanol, merge extractive liquid, after the reflux, drying under reduced pressure get the Fructus Forsythiae total extract with dry Fructus Forsythiae; Again the Fructus Forsythiae total extract is mixed with kieselguhr, or, adopt chloroform extraction Fructus Forsythiae total extract water suspendible, concentrating under reduced pressure, drying promptly gets chloroform extract of Fructus Forsythiae.
Can adopt ethyl acetate, ethanol (n-butyl alcohol) and water extraction successively through the residue Fructus Forsythiae extract behind the chloroform extraction, distinguish concentrating under reduced pressure again, drying can get other Fructus Forsythiae extract.
Described chloroform extract of Fructus Forsythiae can promote the activity of tyrosine phosphatase SHP2, and the effect of performance blood sugar lowering concentration has widely on the medicine of preparation treatment diabetes and uses.
Utilize the reaction of enzyme and substrate, set up the effective SHP2 enzyme activity assay of a maturation system, can high-throughout screening influence the composition of SHP2 enzymatic activity.Utilize the method for GST protein purification, from antibacterial, extract and purification SHP2 albumen.Fluorescence reaction is taken place in SHP2 albumen and its catalytic substrate DiFMUP (8-diXuoro-4-methylumbelliferyl phosphate), utilize the microplate reader reading, establish the use amount of ideal SHP2 albumen and catalytic substrate DiFMUP, set up sensitivity SHP2 enzyme activity assay model efficiently.Utilize described SHP2 enzyme activity assay model, activity to a Chinese medicine separate fraction surplus 2000 is screened, find that described chloroform extract of Fructus Forsythiae has tangible SHP2 enzymatic activity facilitation, and confirm that by zoopery described chloroform extract of Fructus Forsythiae can play the effect of treatment diabetes by this target spot of SHP2.
Description of drawings
Fig. 1 is the facilitations of different Fructus Forsythiae extracts to tyrosine phosphatase SHP2 enzymatic activity.In Fig. 1, abscissa is different Fructus Forsythiae extracts, and concentration is 3.84 μ g/mL, and vertical coordinate is a tyrosine phosphatase SHP2 enzymatic activity (%).
Fig. 2 is the effect of variable concentrations chloroform extract of Fructus Forsythiae to multiple tyrosine phosphatase.In Fig. 2, abscissa is chloroform extract of Fructus Forsythiae concentration (μ g/mL), and vertical coordinate is the promotion rate (%) of chloroform extract of Fructus Forsythiae for different tyrosine phosphatases; Labelling ◆ be SHP2, ■ are SHP1, ▲ be Heptp, ● be VHR.
The specific embodiment
Embodiment 1: the extraction of Fructus Forsythiae extract
Dry Fructus Forsythiae 5kg, 6 times of amount 60% soak with ethanol, reflux 4 times, each 2.5h, merge extractive liquid,, drying under reduced pressure get Fructus Forsythiae total extract 1000g.The Fructus Forsythiae total extract is with the kieselguhr mixing of 3~5 times of amounts, or with total extract water suspendible, the isopyknic chloroform extraction of suspension, concentrating under reduced pressure, drying promptly gets chloroform extract of Fructus Forsythiae 260g.
Extract successively with ethyl acetate, ethanol (or n-butyl alcohol) according to same method again through the residue Fructus Forsythiae extract (aqueous suspension) behind the chloroform extraction, respectively concentrating under reduced pressure, dry each extract.Get Fructus Forsythiae ethyl acetate extract 90g, Fructus Forsythiae ethanol (or n-butyl alcohol) extract 221g and Fructus Forsythiae water extract 400g.
Embodiment 2: Fructus Forsythiae extract is to the facilitation of SHP2
1, the activity rating method of SHP2 facilitation
Utilize the reaction of enzyme and substrate, set up an effective enzyme activity assay system of maturation, can high-throughout screening influence the composition of SHP2 enzymatic activity.Utilize the method for GST protein purification, from antibacterial, extract and purification SHP2 albumen.Fluorescence reaction is taken place in SHP2 albumen and its catalytic substrate DiFMUP (8-diXuoro-4-methylumbelliferyl phosphate), utilize the microplate reader reading, establish the use amount of ideal SHP2 albumen and catalytic substrate DiFMUP, set up sensitivity SHP2 activity analysis efficiently model.Utilize 96 hole ELISA Plate, different fractions or natural micromolecule are added treatment S HP2 activity analysis system, screening promotes the active positive micromolecule of SHP2.The positive micromolecule that screening is obtained is handled the activity analysis system of other tyrosine phosphatases VHR, Heptp, SHP1, and whether analyze them is the active specificity promoter of SHP2.
2, activity rating result
(3.84 μ g/ml) carries out the evaluation of SHP2 enzymatic activity facilitation to the different Fructus Forsythiae extracts among the embodiment 1, the result shows, chloroform extract of Fructus Forsythiae has good SHP2 enzymatic activity facilitation, the Fructus Forsythiae ethyl acetate extract, Fructus Forsythiae ethanol (n-butyl alcohol) extract and Fructus Forsythiae water extract promote that ability is more weak or do not have facilitation (referring to Fig. 1) for the SHP2 enzymatic activity.
Subsequently, chloroform extract of Fructus Forsythiae with variable concentrations, other three member VHR, the Heptp of treatment S HP2 and tyrosine phosphatase enzyme family, SHP1 observe the facilitation of chloroform extract of Fructus Forsythiae to each proteinase activity, estimate its facilitation to the SHP2 enzymatic activity and whether have specificity.The result shows: chloroform extract of Fructus Forsythiae increases with fraction concentration the facilitation of SHP2 enzymatic activity, show good concentration dependent, its other 3 member VHR, Heptp to the tyrosine phosphatase enzyme family, the enzymatic activity of SHP1 do not have obvious facilitation.Show that chloroform extract of Fructus Forsythiae has specificity (referring to Fig. 2) for the facilitation of SHP2.
Embodiment 3: the blood sugar reducing function of chloroform extract of Fructus Forsythiae
Adopt the inductive diabetic mice model of streptozotocin (STZ) to implement.Mice selects for use Kunming white mice male and female to buy during half and half, 4 age in week, in one week of the feeding adaptation of freely drinking water, begins to utilize the streptozotocin modeling.Mice is divided into 2 groups, diabetes-induced group, injection citrate buffer solution group.Before the injection each mice is weighed, mice should first fasting when injecting streptozotocin liquid 6 hours.The diabetes-induced group is according to the ratio lumbar injection STZ-citrate buffer solution (STZ is dissolved in the citrate buffer solution of 0.1mol/L pH4.5) of mice body weight 40mg/kg; The citrate buffer solution of matched group injection equivalent; Injection is 5 days continuously.Subsequently, mice places under the home and raises, and surveys blood glucose value (cut tail and get blood) in per 7 days, and in continuous 3 weeks, the mice of blood glucose value more than 16.7mmol/L is the diabetic mice model under the non-fasted conditions.Press the balanced random packet of blood glucose value, every group of 20 mices, every group of mouse blood sugar average basically identical.With the positive contrast medicine of metformin hydrochloride, the negative contrast of the solvent of chloroform extract of Fructus Forsythiae, chloroform extract of Fructus Forsythiae is established 100mg/kg, 400mg/kg, 3 dosage of 800mg/kg.Other gets 1 group of mice, and intraperitoneal injection of saline is irritated stomach according to the amount of 0.02ml/g to mice according to the mice body weight as the normal control group, once a day, and continuous two weeks.In at 10 o'clock in the morning every day mice is carried out fasting, fasting is irritated stomach to mice after 6 hours again.At the 7th day and the 14th day, fasting 3h respectively surveyed blood glucose once.
The result is as shown in table 1, and the chloroform extract of Fructus Forsythiae of 3 various dose all shows the effect of tangible blood sugar lowering.
Table 1 forsythia chloroform layer extract is to the effect of mouse blood sugar
A. compare the p value of t-check with the solvent model group.*p<0.05,**p<0.01。

Claims (2)

1. the application of chloroform extract of Fructus Forsythiae in preparation tyrosine phosphatase SHP2 promoter.
2. the application of chloroform extract of Fructus Forsythiae in preparation treatment diabetes medicament.
CN2010102564759A 2010-08-19 2010-08-19 Application of forsythia chloroform extracts in preparing medicine for treating diabetes mellitus Expired - Fee Related CN101912446B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2010102564759A CN101912446B (en) 2010-08-19 2010-08-19 Application of forsythia chloroform extracts in preparing medicine for treating diabetes mellitus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2010102564759A CN101912446B (en) 2010-08-19 2010-08-19 Application of forsythia chloroform extracts in preparing medicine for treating diabetes mellitus

Publications (2)

Publication Number Publication Date
CN101912446A true CN101912446A (en) 2010-12-15
CN101912446B CN101912446B (en) 2011-11-09

Family

ID=43320193

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010102564759A Expired - Fee Related CN101912446B (en) 2010-08-19 2010-08-19 Application of forsythia chloroform extracts in preparing medicine for treating diabetes mellitus

Country Status (1)

Country Link
CN (1) CN101912446B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102210333A (en) * 2011-04-21 2011-10-12 北京农学院 New use of forsythia suspense in plant mite killing
CN103432207A (en) * 2013-09-14 2013-12-11 河南中医学院 Preparation method of fructus forsythiae extract lignan and application of extract in blood sugar reducing drugs
CN108542936A (en) * 2018-04-19 2018-09-18 浦江县美泽生物科技有限公司 A kind of forsythia suspense extraction

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1521157A (en) * 2003-02-14 2004-08-18 中国科学院上海药物研究所 Protein tyrosine phosphatase 1B inhibitor para-benzoquinone compound and process for preparing the same
CN101618075A (en) * 2008-07-03 2010-01-06 河南大学 Blood-sugar-lowering effective parts of traditional Chinese medicine weeping forsythia, extracting method and application thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1521157A (en) * 2003-02-14 2004-08-18 中国科学院上海药物研究所 Protein tyrosine phosphatase 1B inhibitor para-benzoquinone compound and process for preparing the same
CN101618075A (en) * 2008-07-03 2010-01-06 河南大学 Blood-sugar-lowering effective parts of traditional Chinese medicine weeping forsythia, extracting method and application thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
> 20080831 曲欢欢 连翘化学成分和生物活性研究 全文 1-2 , 第8期 2 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102210333A (en) * 2011-04-21 2011-10-12 北京农学院 New use of forsythia suspense in plant mite killing
CN102210333B (en) * 2011-04-21 2013-05-01 北京农学院 New use of forsythia suspense in plant mite killing
CN103432207A (en) * 2013-09-14 2013-12-11 河南中医学院 Preparation method of fructus forsythiae extract lignan and application of extract in blood sugar reducing drugs
CN103432207B (en) * 2013-09-14 2015-04-01 河南中医学院 Preparation method of fructus forsythiae extract lignan and application of extract in blood sugar reducing drugs
CN108542936A (en) * 2018-04-19 2018-09-18 浦江县美泽生物科技有限公司 A kind of forsythia suspense extraction
CN108542936B (en) * 2018-04-19 2021-05-04 浦江县美泽生物科技有限公司 Forsythia suspensa extract

Also Published As

Publication number Publication date
CN101912446B (en) 2011-11-09

Similar Documents

Publication Publication Date Title
Oh et al. Antidiabetic effects of extracts from Psidium guajava
Youn et al. Anti-hyperglycemic activity of Commelina communis L.: inhibition of α-glucosidase
Ramu et al. The effect of a plant extract enriched in stigmasterol and β-sitosterol on glycaemic status and glucose metabolism in alloxan-induced diabetic rats
Xie et al. Effect of ethanolic extracts of Ananas comosus L. leaves on insulin sensitivity in rats and HepG2
CN101229316B (en) Rhizoma anemarrhenae extrac
CN101181446B (en) Application of sitsang scindapsus aureus flower as well as extract thereof in the preparation of diabetes medicament
CA2710862C (en) Pharmaceutical composition for treating diabetes and preparation method thereof
CN101912446B (en) Application of forsythia chloroform extracts in preparing medicine for treating diabetes mellitus
Mokashi et al. Swertisin rich fraction from Enicostema littorale ameliorates hyperglycemia and hyperlipidemia in high-fat fed diet and low dose streptozotacin induced type 2 diabetes mellitus in rats
CN112645808A (en) 5-hydroxy-1, 7-diphenyl-3-heptanone separated from galangal and application thereof
CN103110697A (en) Pharmaceutical composition with hypoglycemic effect
JP6701583B2 (en) Composition for treating type 1 diabetes mellitus
CN1618446A (en) Medicine for treating diabetes, and its prepn. method
CN112552155A (en) 1, 7-diphenyl-4-heptylene-3-ketone separated from galangal and application thereof
CN102068475B (en) Application and blood-sugar lowering effective part of trapa acornis nakano shell as well as extraction method of blood-sugar lowering effective part
Li et al. Hypoglycemic effect of polysaccharides of Dendrobium officinale compound on type 2 diabetic mice
KR102036302B1 (en) Composition for preventing or treating metabolic syndrome comprising extracts of Selaginella rossii Warb., a fraction thereof
CN101411781A (en) Use of pu'er tea in preparing medicament for treating or preventing diabetes
CN101491605A (en) Combination with blood sugar reducing function and preparation method thereof
Jaafar et al. ANTIDIABETIC EFFECTS OF KNEMA GLAUCA LEAF EXTRACT TOWARD INHIBITIONS OF Î ‘-AMYLASE AND Î ‘-GLUCOSIDASE ASSAYS
CN107260946A (en) A kind of health-care edible capsule preparation method with auxiliary hyperglycemic function
CN100356943C (en) Medicinal composition for treating diabetes
CN106822095A (en) A kind of medicine and its application in pharmacy for preventing and treating fatty liver and obesity
CN112451558A (en) Application of beautiful millettia root alcohol extract in preparing hypoglycemic or hypolipemic drugs and health products
KR100692560B1 (en) Amylase Inhibitor for Anti-obesity and Use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20111109

Termination date: 20170819

CF01 Termination of patent right due to non-payment of annual fee